-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMP-17 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMP-17 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMP-17 in Solid Tumor Drug Details: IMP-17 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMP-17 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMP-17 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMP-17 in Ovarian Cancer Drug Details: IMP-17 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMP-17 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMP-17 in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMP-17 in Peritoneal Cancer Drug Details: IMP-17 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMP-17 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMP-17 in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMP-17 in Metastatic Breast Cancer Drug Details: IMP-17 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMP-17 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMP-17 in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMP-17 in Fallopian Tube Cancer Drug Details: IMP-17 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMP-17 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMP-17 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMP-17 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Non-Small Cell Lung Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Non-Small Cell Lung Carcinoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Soft Tissue Sarcoma Drug Details: Eftilagimod...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Angiosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Angiosarcoma Drug Details: Eftilagimod alfa (IMP-321, EDP-202) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Dedifferentiated Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Dedifferentiated Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Dedifferentiated Liposarcoma Drug Details: Eftilagimod alfa (IMP-321,...